Sentiment Summary
Recent Events
Q3 2025/26 earnings release scheduled. (Low importance estimated for a routine scheduled event).
Q2 2026 earnings results and conference call for July 29, 2026, before market open scheduled
Analysts forecast the next quarterly earnings release for 2026-07-23 estimated. Estimated Medium importance as earnings reports typically drive significant price volatility.
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
Ex-dividend date on June 19, 2026, for the proposed annual dividend of CHF 4.70 per share for the 2025/26 financial year, representing a 7% increase from the prior year. This is expected to have a low positive impact as it reflects stable cash flow scheduled.
Ex-dividend date on 2026-06-18 for the FY2025 final dividend of RMB 1.26 per 10 shares, with payment scheduled on or before 2026-07-31; scheduled.
Company executive leadership to participate in a fireside chat at the Truist Securities 2026 MedTech Conference on 2026-06-16 scheduled.
Annual General Meeting scheduled for June 16, 2026, where shareholders will vote on proposals including a dividend of CHF 4.70 per share and the election of three new board members. This is expected to have a neutral impact as a routine event scheduled.
The 2025 Annual General Meeting to approve the profit distribution plan and annual report on June 12, 2026; market reaction is estimated at Low as it is a routine meeting scheduled.
Alphabet held its 2026 Annual Meeting of Shareholders on June 5, 2026. Proposals included an increase to the 2021 Stock Plan share reserve.
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
The company presented positive Phase III trial data for its 'Defu Combination' (Anlotinib plus Bemotuzumab) as a first-line treatment for non-squamous non-small cell lung cancer (nsq-NSCLC) at the 2026 ASCO meeting, showing a significant 6-month improvement in median Progression-Free Survival (mPFS) compared to the control group.
Announced repurchase of 812,400 H-shares for approximately HK$101 million on June 4, 2026, as part of an ongoing share buyback program; low importance as the buyback is routine and likely to result in >=1% price impact.
The New Drug Application (NDA) for Olipudase (奥莱泊肽), a GLP-1/GIP dual receptor agonist, was accepted for review by China's NMPA on June 3, 2026. Analysts estimate a >10% price impact due to the drug's significant market potential expected.
Reported Q4 and full-year fiscal 2026 results on June 3, 2026, with quarterly revenue of $9.8 billion, beating estimates, and non-GAAP EPS of $1.55. The company delivered its highest annual revenue growth in 10 years and provided FY27 organic revenue growth guidance of 6.75% to 7.25%.
The company announced positive interim data from a Phase II study of Ivonescimab for first-line metastatic colorectal cancer (mCRC) at ASCO 2026, showing a 70.8% objective response rate and 100% disease control rate. Medium importance is estimated as Phase II data typically results in a 5-10% price impact scheduled.
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
Announced on June 3, 2026, the submission of 510(k) filings to the FDA to expand the indications for its Hugo robotic-assisted surgery system to include general and gynecologic surgeries, major growth areas.
The Board of Directors approved an increase in the quarterly dividend to $0.72 per share on June 3, 2026, marking the 49th consecutive year of dividend increases. The ex-dividend date is June 26, 2026.
Stockholders approved an amendment to the 2021 Equity Incentive Plan on 2026-06-03, increasing authorized shares by 1,000,000 to a total of 12,000,000; as this is a routine corporate governance matter, low impact expected
The UK's Competition & Markets Authority (CMA) announced on June 3, 2026, new conduct requirements for Google's AI-powered search, giving publishers more control over their content.
Kelun-Biotech announced positive first-in-human study results for its novel B7-H3 ADC drug, SKB500, at the 2026 ASCO annual meeting on June 2, 2026. The data showed broad-spectrum antitumor activity across multiple solid tumors, with notable efficacy in small cell lung cancer (SCLC).
Following the AGM on 2026-06-02, Dr. Ye Xiaoping was re-elected as Chairman and Mr. Wen Zengyu was appointed as General Manager; low impact expected from routine leadership continuity.
Akeso announced that its drug Ivonescimab plus chemotherapy showed a 34% reduction in the risk of death in the Phase III HARMONi-6 trial for first-line advanced squamous non-small cell lung cancer. The landmark results were presented at the ASCO 2026 Plenary Session and published in The Lancet. High importance is estimated due to the significant clinical success in a major indication, likely resulting in >10% price impact scheduled.
Alphabet announced an $80 billion equity capital raise on June 1, 2026, to fund AI infrastructure, including a $10 billion investment from Berkshire Hathaway. The offering was upsized to approximately $85 billion on June 3, 2026, due to high demand. This massive capital raise is expected to have a high price impact due to significant dilution.
Presentation of positive long-term follow-up data for IBI363 (PD-1/IL-2) at the 2026 ASCO annual meeting; 5-10% price impact estimated due to clinical data validation scheduled
Provided a business update on June 1, 2026, maintaining full-year 2026 revenue growth guidance of 13-17% and reporting 69 new projects; medium importance reflects an estimated price impact of 5% or more.
Ex-dividend date on June 1, 2026, for a final dividend of RMB 0.5390 and a special dividend of RMB 0.6714. Low importance estimated as dividend payouts typically result in minor price adjustments; scheduled.
Stefano Folli scheduled to become the new President of the Cardiopulmonary business unit on June 1, 2026.
Announced two breakthroughs: its innovative peptide food ingredient, Tensotide, received US Self-GRAS certification, and its incubated company's solid tumor drug, SIGX2649, received US FDA IND approval.
The company announced on May 31, 2026, that its Phase III study (OptiTROP-Lung05) of sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab for first-line treatment of PD-L1 positive NSCLC met its primary endpoint.
On May 31, 2026, Johnson & Johnson announced positive final results from the Phase 3 PROTEUS study of ERLEADA in prostate cancer; successful Phase 3 results for an oncology blockbuster typically drive a 5-10% price impact, expected.
Announcement of strategic global licensing agreement with Pfizer for 12 cancer medicines ($10.5B total value); >10% price impact estimated due to massive deal size expected
The company announced positive pivotal data from two Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen for the treatment of chronic hepatitis B, which were presented at the 2026 European Association for the Study of the Liver (EASL) Congress and published in the New England Journal of Medicine.
RemeGen's shares were included in the MSCI China Index, effective after market close on May 29, 2026. Analysts estimate this will drive institutional demand with a price impact of at least 5%, estimated.
Announced that subsidiary Shanghai Henlius Biotech's Pertuzumab Injection (brand name 汉倍优®) was approved for marketing by China's NMPA. Low importance as subsidiary product approvals typically have a limited price impact (<5%).
Announced on May 29, 2026, that a trustee purchased approximately 5.7 million shares on the open market between May 19 and May 29 for the company's share award scheme.
Ex-dividend date on May 29, 2026, for a final dividend of CNY 1.57927 per share for the year 2025; low importance as the price adjustment is expected to be >=1%.